nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—Overview of nanoparticle effects—CCND3—ocular cancer	0.0512	0.0512	CbGpPWpGaD
Pomalidomide—TNF—Monoamine Transport—RBL2—ocular cancer	0.0424	0.0424	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—CCND3—ocular cancer	0.0316	0.0316	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—RBBP4—ocular cancer	0.0214	0.0214	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—HDAC1—ocular cancer	0.0174	0.0174	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—E2F5—ocular cancer	0.0169	0.0169	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—CCND3—ocular cancer	0.0167	0.0167	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—H1F0—ocular cancer	0.0154	0.0154	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—E2F4—ocular cancer	0.0153	0.0153	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—RBL1—ocular cancer	0.015	0.015	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—HDAC1—ocular cancer	0.0144	0.0144	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—RBL2—ocular cancer	0.0138	0.0138	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—E2F1—ocular cancer	0.0133	0.0133	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—ID2—ocular cancer	0.0126	0.0126	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—E2F1—ocular cancer	0.0124	0.0124	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—GNAQ—ocular cancer	0.0116	0.0116	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—HDAC1—ocular cancer	0.0115	0.0115	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—CDK2—ocular cancer	0.0115	0.0115	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—E2F4—ocular cancer	0.0113	0.0113	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—RBL1—ocular cancer	0.011	0.011	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TFDP1—ocular cancer	0.0105	0.0105	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CCND3—ocular cancer	0.0105	0.0105	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—E2F5—ocular cancer	0.0105	0.0105	CbGpPWpGaD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—ocular cancer	0.0101	0.0101	CbGpPWpGaD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—RB1—ocular cancer	0.0101	0.0101	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—RB1—ocular cancer	0.00942	0.00942	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—RB1—ocular cancer	0.00911	0.00911	CbGpPWpGaD
Pomalidomide—TNF—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—ocular cancer	0.00884	0.00884	CbGpPWpGaD
Pomalidomide—TNF—IL27-mediated signaling events—TGFB1—ocular cancer	0.00884	0.00884	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—TGFB1—ocular cancer	0.00858	0.00858	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—E2F1—ocular cancer	0.00822	0.00822	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDK6—ocular cancer	0.00783	0.00783	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—E2F1—ocular cancer	0.00769	0.00769	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ocular cancer	0.00734	0.00734	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—CDKN1B—ocular cancer	0.00734	0.00734	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CDK6—ocular cancer	0.00718	0.00718	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—CDK4—ocular cancer	0.00718	0.00718	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDK2—ocular cancer	0.00709	0.00709	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—E2F4—ocular cancer	0.00697	0.00697	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RBL1—ocular cancer	0.00683	0.00683	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—CDKN1A—ocular cancer	0.00677	0.00677	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—CDKN1B—ocular cancer	0.00655	0.00655	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—EP300—ocular cancer	0.00644	0.00644	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—EP300—ocular cancer	0.00644	0.00644	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—ocular cancer	0.00633	0.00633	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—ocular cancer	0.00627	0.00627	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—E2F1—ocular cancer	0.00626	0.00626	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—HDAC1—ocular cancer	0.00608	0.00608	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—CDKN1A—ocular cancer	0.00604	0.00604	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—RB1—ocular cancer	0.00583	0.00583	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—E2F1—ocular cancer	0.00579	0.00579	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—EP300—ocular cancer	0.00567	0.00567	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—MYC—ocular cancer	0.00561	0.00561	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—TGFB1—ocular cancer	0.0056	0.0056	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—MYC—ocular cancer	0.00543	0.00543	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CDK2—ocular cancer	0.0054	0.0054	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—ocular cancer	0.00537	0.00537	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CDK4—ocular cancer	0.0051	0.0051	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—E2F1—ocular cancer	0.00503	0.00503	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—MDM2—ocular cancer	0.00496	0.00496	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—E2F4—ocular cancer	0.00494	0.00494	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—TGFB1—ocular cancer	0.00493	0.00493	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—TGFB1—ocular cancer	0.00485	0.00485	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RBL1—ocular cancer	0.00484	0.00484	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—E2F1—ocular cancer	0.00465	0.00465	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CDKN2B—ocular cancer	0.00464	0.00464	CbGpPWpGaD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—EP300—ocular cancer	0.0046	0.0046	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—ocular cancer	0.00454	0.00454	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—RB1—ocular cancer	0.00444	0.00444	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—HRAS—ocular cancer	0.00441	0.00441	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—EP300—ocular cancer	0.00427	0.00427	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—E2F1—ocular cancer	0.00426	0.00426	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—ocular cancer	0.00419	0.00419	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—AKT1—ocular cancer	0.00419	0.00419	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—RB1—ocular cancer	0.0041	0.0041	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—CDK2—ocular cancer	0.00401	0.00401	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—EP300—ocular cancer	0.00398	0.00398	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—HRAS—ocular cancer	0.00388	0.00388	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—E2F1—ocular cancer	0.00387	0.00387	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CCND3—ocular cancer	0.00378	0.00378	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—AKT1—ocular cancer	0.00376	0.00376	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—TGFB1—ocular cancer	0.00371	0.00371	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CDK2—ocular cancer	0.00367	0.00367	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—AKT1—ocular cancer	0.00364	0.00364	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—TGFB1—ocular cancer	0.00363	0.00363	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—ocular cancer	0.00355	0.00355	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—ocular cancer	0.00348	0.00348	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—ocular cancer	0.00347	0.00347	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CDK4—ocular cancer	0.00347	0.00347	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—MYC—ocular cancer	0.00347	0.00347	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—ocular cancer	0.00346	0.00346	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—TP53—ocular cancer	0.00345	0.00345	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CDKN1B—ocular cancer	0.00345	0.00345	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—AKT1—ocular cancer	0.00337	0.00337	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CDK2—ocular cancer	0.00334	0.00334	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—HRAS—ocular cancer	0.0033	0.0033	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—RB1—ocular cancer	0.0033	0.0033	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CCND1—ocular cancer	0.00329	0.00329	CbGpPWpGaD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—AKT1—ocular cancer	0.00328	0.00328	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CDK4—ocular cancer	0.00315	0.00315	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—ocular cancer	0.00306	0.00306	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—TP53—ocular cancer	0.00299	0.00299	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—CDKN1A—ocular cancer	0.00295	0.00295	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—ocular cancer	0.00287	0.00287	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—ocular cancer	0.00285	0.00285	CbGpPWpGaD
Pomalidomide—CYP1A2—Tryptophan metabolism—MDM2—ocular cancer	0.00281	0.00281	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CDKN1B—ocular cancer	0.0028	0.0028	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—RB1—ocular cancer	0.00274	0.00274	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—ocular cancer	0.00273	0.00273	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CCND1—ocular cancer	0.00267	0.00267	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—MYC—ocular cancer	0.00264	0.00264	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TGFB1—ocular cancer	0.00264	0.00264	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—E2F1—ocular cancer	0.00263	0.00263	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CDKN1A—ocular cancer	0.00259	0.00259	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MDM2—ocular cancer	0.00257	0.00257	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ocular cancer	0.00257	0.00257	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—ocular cancer	0.00257	0.00257	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—HRAS—ocular cancer	0.00253	0.00253	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—EP300—ocular cancer	0.00246	0.00246	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—TGFB1—ocular cancer	0.00244	0.00244	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—EP300—ocular cancer	0.00243	0.00243	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—AKT1—ocular cancer	0.0024	0.0024	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—AKT1—ocular cancer	0.0024	0.0024	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—ocular cancer	0.00237	0.00237	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CDKN1B—ocular cancer	0.00235	0.00235	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ocular cancer	0.00234	0.00234	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDK2—ocular cancer	0.00227	0.00227	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PSPH—ocular cancer	0.00226	0.00226	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—ocular cancer	0.00225	0.00225	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—ocular cancer	0.00225	0.00225	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CCND1—ocular cancer	0.00224	0.00224	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—AKT1—ocular cancer	0.00224	0.00224	CbGpPWpGaD
Pomalidomide—CYP3A4—Tryptophan metabolism—MDM2—ocular cancer	0.00217	0.00217	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TP53—ocular cancer	0.00217	0.00217	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CDKN1A—ocular cancer	0.00217	0.00217	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—ocular cancer	0.00215	0.00215	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—MYC—ocular cancer	0.00214	0.00214	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CDKN1B—ocular cancer	0.00214	0.00214	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—EP300—ocular cancer	0.00212	0.00212	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EP300—ocular cancer	0.00206	0.00206	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—AKT1—ocular cancer	0.00206	0.00206	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CCND1—ocular cancer	0.00204	0.00204	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—ocular cancer	0.00203	0.00203	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MYC—ocular cancer	0.00199	0.00199	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TGFB1—ocular cancer	0.00199	0.00199	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—ocular cancer	0.00196	0.00196	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—ocular cancer	0.00196	0.00196	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—E2F1—ocular cancer	0.00187	0.00187	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MYC—ocular cancer	0.0018	0.0018	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TGFB1—ocular cancer	0.00179	0.00179	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SAG—ocular cancer	0.00178	0.00178	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—ocular cancer	0.00174	0.00174	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—HRAS—ocular cancer	0.00168	0.00168	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—ocular cancer	0.00164	0.00164	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MYC—ocular cancer	0.00163	0.00163	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TGFB1—ocular cancer	0.00163	0.00163	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CDK4—ocular cancer	0.00162	0.00162	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDK2—ocular cancer	0.00161	0.00161	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—AKT1—ocular cancer	0.00161	0.00161	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PSPH—ocular cancer	0.0016	0.0016	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TGFB1—ocular cancer	0.00159	0.00159	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—ocular cancer	0.00159	0.00159	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—E2F5—ocular cancer	0.00158	0.00158	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—E2F4—ocular cancer	0.00155	0.00155	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ocular cancer	0.00154	0.00154	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—ocular cancer	0.00152	0.00152	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—RPL39—ocular cancer	0.00152	0.00152	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—RBL1—ocular cancer	0.00152	0.00152	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—ocular cancer	0.00148	0.00148	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—AKT1—ocular cancer	0.00147	0.00147	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—ocular cancer	0.00145	0.00145	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—ocular cancer	0.00139	0.00139	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—AKT1—ocular cancer	0.00138	0.00138	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—ocular cancer	0.00134	0.00134	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—ocular cancer	0.00134	0.00134	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—ocular cancer	0.00128	0.00128	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PSPH—ocular cancer	0.00128	0.00128	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—ocular cancer	0.00128	0.00128	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—AKT1—ocular cancer	0.00125	0.00125	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TFDP1—ocular cancer	0.00122	0.00122	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—ocular cancer	0.00113	0.00113	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—ocular cancer	0.00111	0.00111	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—ocular cancer	0.00111	0.00111	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ocular cancer	0.00103	0.00103	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PSPH—ocular cancer	0.000985	0.000985	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ocular cancer	0.000982	0.000982	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MAML2—ocular cancer	0.000972	0.000972	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EP300—ocular cancer	0.000964	0.000964	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—ocular cancer	0.00095	0.00095	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—ocular cancer	0.000913	0.000913	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—ocular cancer	0.000904	0.000904	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—TGFB1—ocular cancer	0.000838	0.000838	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ocular cancer	0.000788	0.000788	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—ocular cancer	0.000786	0.000786	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—ocular cancer	0.000771	0.000771	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HDAC1—ocular cancer	0.00071	0.00071	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GNA11—ocular cancer	0.00071	0.00071	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GNAQ—ocular cancer	0.00066	0.00066	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—HRAS—ocular cancer	0.00066	0.00066	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ocular cancer	0.000647	0.000647	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN2B—ocular cancer	0.000637	0.000637	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—AKT1—ocular cancer	0.000583	0.000583	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ocular cancer	0.000546	0.000546	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—ocular cancer	0.000533	0.000533	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GNA11—ocular cancer	0.000503	0.000503	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GNAQ—ocular cancer	0.000468	0.000468	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GNA11—ocular cancer	0.000402	0.000402	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GNAQ—ocular cancer	0.000374	0.000374	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MDM2—ocular cancer	0.000353	0.000353	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1B—ocular cancer	0.000323	0.000323	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GNA11—ocular cancer	0.00031	0.00031	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—ocular cancer	0.000301	0.000301	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1A—ocular cancer	0.000298	0.000298	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GNAQ—ocular cancer	0.000288	0.000288	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EP300—ocular cancer	0.000283	0.000283	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MYC—ocular cancer	0.000247	0.000247	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TGFB1—ocular cancer	0.000246	0.000246	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—EP300—ocular cancer	0.000237	0.000237	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HRAS—ocular cancer	0.000194	0.000194	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AKT1—ocular cancer	0.000171	0.000171	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—EP300—ocular cancer	0.000168	0.000168	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AKT1—ocular cancer	0.000143	0.000143	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—EP300—ocular cancer	0.000134	0.000134	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—EP300—ocular cancer	0.000104	0.000104	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKT1—ocular cancer	0.000102	0.000102	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKT1—ocular cancer	8.11e-05	8.11e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKT1—ocular cancer	6.26e-05	6.26e-05	CbGpPWpGaD
